DR-490 Detection of DNA damage response (DDR) dysfunction from tumor sequencing data
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-490 Detection of DNA damage response (DDR) dysfunction from tumor sequencing data
To continue unchecked growth, cancer cells bypass mechanisms that protect our genomic code, such as DNA repair and telomere maintenance. …
DR-482 Decoding the role of complex genomic rearrangements in driving metastasis, cancer genome evolution and drug resistance
Over the last years, my laboratory has revealed that cancer genomes are riddled by complex forms of structural variants (SVs), …
DR-500 Somatic mutagenesis in cancer: characterization, models and methods for driver detection
This project aims to generate new knowledge about mutational processes in tumors and to develop improved computational methodology for finding …
DR-487 Pan-cancer landscapes of transcriptional and genomic heterogeneity in metastatic tumors
Metastasis, the spread of cancer from its original site to other organs, is the leading cause of cancer-related deaths. This …
DR-489 Adapting the DeepTumour Algorithm to Plasma Whole Genome Sequencing
The major factor predicting a human cancer’s behaviour is its organ of origin. However, roughly 3% of the time a …
DR-509 Clinical utility and genomic predictors of treatment (non-)response in metastatic colorectal cancer
Metastatic colorectal cancer is treated with chemotherapy and targeted drugs. Although recent studies have identified genes that may predict how …
DR-505 Pan-cancer validation of complementary RNA-seq signatures for HER2 overexpression using Hartwig genomic and transcriptomic data
Patients can benefit from HER2-targeted therapies when their tumors show HER2 activation, but current testing (IHC/FISH) is not always available …
DR-486 Integrated Analysis of Mitochondrial Somatic Variants, Chromosomal Instability, and Extrachromosomal DNA in Human Metastatic Cancer: A Multi-Omics Approach Using Hartwig Whole Genome Data
Cancer cells accumulate multiple types of genetic damage that work together to make tumors more aggressive and harder to treat. …
DR-480 Biomarker and Pattern Discovery and Validation
When analysing genomic, transcriptomic, epigenetic and clinical data from cancer patients, response to treatment can be related to the occurrence …
DR-473 Investigating the molecular background of rare anogenital sqaumous cell carcinomas, to unveil the tumor driving events in HPV-positive and HPV-negative tumors and find differences and similarities between tumor types.
Penile, vaginal, vulvar, and anal cancer are rare types of (anogenital) cancer, and a lot is unknown about tumor biology. …
DR-484 Analysis of germline mutations to discover novel biomarkers for prognosis and treatment response
This project investigates how inherited (germline) genetic mutations affect cancer outcomes. While some well-known “driver” mutations, such as those in …
DR-483 Characterization of the evolutionary dynamics of mutational signatures for clinically actionable cancer genomics
We aim to decode how cancers mutate their DNA over time and use that knowledge to improve patient care. Using …
Het feit dat het CPCT het samen met Hartwig Medical Foundation voor elkaar heeft gekregen om data, kennis en kunde van vrijwel alle Nederlandse ziekenhuizen te bundelen, is uniek en krijgt inmiddels ook internationale aandacht.